AU1113097A - Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof - Google Patents
Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereofInfo
- Publication number
- AU1113097A AU1113097A AU11130/97A AU1113097A AU1113097A AU 1113097 A AU1113097 A AU 1113097A AU 11130/97 A AU11130/97 A AU 11130/97A AU 1113097 A AU1113097 A AU 1113097A AU 1113097 A AU1113097 A AU 1113097A
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- cytokine
- endogenous production
- salt form
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 3
- 108090000695 Cytokines Proteins 0.000 title abstract 3
- 230000002607 hemopoietic effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 title 1
- 108010053070 Glutathione Disulfide Proteins 0.000 abstract 4
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 abstract 4
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 abstract 4
- 150000003839 salts Chemical group 0.000 abstract 4
- 239000004606 Fillers/Extenders Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU95120403/14A RU2089179C1 (ru) | 1995-12-14 | 1995-12-14 | Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования |
| RO95120403 | 1995-12-14 | ||
| WORU9600226 | 1996-08-08 | ||
| PCT/RU1996/000226 WO1997021443A1 (en) | 1995-12-14 | 1996-08-08 | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
| PCT/RU1996/000340 WO1997021444A1 (en) | 1995-12-14 | 1996-12-10 | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1113097A true AU1113097A (en) | 1997-07-03 |
Family
ID=26653679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU11130/97A Abandoned AU1113097A (en) | 1995-12-14 | 1996-12-10 | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0869809B1 (enExample) |
| JP (2) | JP2000515111A (enExample) |
| AT (1) | ATE214936T1 (enExample) |
| AU (1) | AU1113097A (enExample) |
| CA (1) | CA2239874A1 (enExample) |
| DE (1) | DE69620233T2 (enExample) |
| ES (1) | ES2174124T3 (enExample) |
| WO (1) | WO1997021444A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040101576A1 (en) * | 1997-03-21 | 2004-05-27 | Eiichiro Yagi | Immunopotentiators |
| IL123887A0 (en) * | 1997-04-02 | 1998-10-30 | Sankyo Co | Dithiolan derivatives their use and pharmaceutical compositions containing the same |
| US6399372B1 (en) | 1998-03-30 | 2002-06-04 | I.D.M. Immuno-Designed | Monocyte derived cells with immunostimulating properties, their preparation and uses |
| JP2000169371A (ja) * | 1998-10-02 | 2000-06-20 | Sankyo Co Ltd | ジチオラン誘導体を含有する医薬 |
| US6312734B1 (en) * | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| RU2144374C1 (ru) | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток |
| US20070142267A1 (en) | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| RU2229892C2 (ru) * | 2001-06-08 | 2004-06-10 | Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" | Способ лечения туберкулеза легких |
| US7173013B2 (en) | 2001-06-08 | 2007-02-06 | Sciclone Pharmaceuticals, Inc. | Treatment of tuberculosis using immunomodulator compounds |
| JP2006515629A (ja) * | 2003-01-23 | 2006-06-01 | シャイア ラボラトリーズ，インコーポレイテッド | 吸収促進剤 |
| RU2482868C1 (ru) * | 2011-12-30 | 2013-05-27 | Общество С Ограниченной Ответственностью "Ива Фарм" | Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний |
| JP6469568B2 (ja) * | 2012-09-28 | 2019-02-13 | 協和発酵バイオ株式会社 | グルタチオンを含有する免疫増強剤 |
| RU2545900C2 (ru) * | 2013-05-07 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ диагностики апоптоза лимфоцитов |
| RU2540500C2 (ru) * | 2013-05-07 | 2015-02-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ прогнозирования ранней стадии апоптоза |
| RU2659161C1 (ru) | 2017-11-17 | 2018-06-28 | Общество С Ограниченной Ответственностью "Ива Фарм" | Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид |
| CN114617899B (zh) * | 2022-04-14 | 2023-10-20 | 苏州大学附属儿童医院 | S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277619A (ja) * | 1985-06-04 | 1986-12-08 | Otsuka Pharmaceut Factory Inc | 肝疾患治療剤 |
| JP2921124B2 (ja) * | 1990-12-28 | 1999-07-19 | 千寿製薬株式会社 | 酸化型グルタチオンアルキルエステル |
| US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
| US5618823A (en) * | 1992-06-24 | 1997-04-08 | Boehringer Mannheim Italia S.P.A. | Glutathione as chemoprotective agent |
| GB9303854D0 (en) * | 1993-02-25 | 1993-04-14 | Holt John A G | Method for enhancing t-cell count |
-
1996
- 1996-12-10 AU AU11130/97A patent/AU1113097A/en not_active Abandoned
- 1996-12-10 DE DE69620233T patent/DE69620233T2/de not_active Expired - Lifetime
- 1996-12-10 ES ES96941915T patent/ES2174124T3/es not_active Expired - Lifetime
- 1996-12-10 JP JP09521965A patent/JP2000515111A/ja not_active Withdrawn
- 1996-12-10 EP EP96941915A patent/EP0869809B1/en not_active Expired - Lifetime
- 1996-12-10 WO PCT/RU1996/000340 patent/WO1997021444A1/en not_active Ceased
- 1996-12-10 CA CA002239874A patent/CA2239874A1/en not_active Abandoned
- 1996-12-10 AT AT96941915T patent/ATE214936T1/de active
-
2007
- 2007-09-13 JP JP2007238577A patent/JP2008001722A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69620233D1 (de) | 2002-05-02 |
| WO1997021444A1 (en) | 1997-06-19 |
| ES2174124T3 (es) | 2002-11-01 |
| DE69620233T2 (de) | 2002-11-14 |
| JP2000515111A (ja) | 2000-11-14 |
| EP0869809B1 (en) | 2002-03-27 |
| EP0869809A1 (en) | 1998-10-14 |
| JP2008001722A (ja) | 2008-01-10 |
| CA2239874A1 (en) | 1997-06-19 |
| ATE214936T1 (de) | 2002-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1113097A (en) | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof | |
| GEP20002146B (en) | Therapeutic Peptide Derivatives | |
| AU2267192A (en) | Treatment of migraine by nerve stimulation | |
| EP2158907A3 (en) | Topical administration of arginine for pain treatment | |
| AU4515985A (en) | New tetrapyrrole therapeutic agents | |
| AU1773792A (en) | Device for reducing sensation during iontophoretic drug delivery | |
| PL331325A1 (en) | Isobutylgabe and its derivatives useful in relieving pains | |
| EP0841074A3 (en) | Medical apparatus | |
| NO960445D0 (no) | Hudplaster og fremgangsmåter for å administrere testosteron | |
| AU2259292A (en) | Treatment of neuropsychiatric disorders by nerve stimulation | |
| IE832037L (en) | Iontophoretic treatment | |
| AU3309097A (en) | Reduction of skin sensitization in electrotransport drug delivery | |
| CA2149924A1 (en) | Use of phenserine to treat cognitive disorders | |
| PL323798A1 (en) | Application of derivatives of vitamin d4 in treating skin diseases | |
| AU8502198A (en) | Method for treating vascular proliferative diseases with p27 and fusions thereof | |
| AU5691796A (en) | Terpenoidic derivatives useful as antitumor agents | |
| NZ303993A (en) | Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders | |
| MD185C2 (ro) | Metodă de tratament al şocului | |
| AU6955396A (en) | Combination therapy for advanced cancer comprising temozolomide and cisplatin | |
| AU4042795A (en) | Treatment of non-small cell lung carcinoma | |
| AU7373196A (en) | Combination of temozolomide and alpha-ifn for the treatment of advanced cancer | |
| RU97121729A (ru) | Способ стимуляции репаративного остеогенеза | |
| AU6521500A (en) | Gene therapy platformed needle and method of administering therapeutic solution to a heart | |
| UA39768A (uk) | Спосіб лікування хворих зі спазмом акомодації | |
| UA30696A (uk) | Спосіб комплексного лікування пародонтиту |